Dementia Vaccine Is Being Clinically Tested

The development of humanity follows the path of continuous increase in life expectancy, however, one of the most formidable problems of older people remains relevant – the development of senile dementia, as well as Alzheimer’s disease. An international team of scientists from the USA and Australia proposed a method of vaccination against such diseases, based on a decrease in the intensity of accumulation of amyloids and tau proteins in the human brain.

Representatives of the University of California and the Institute of Molecular Medicine, together with Professor Nikolai Petrovsky of Flinders University (South Australia), are exploring a hypothesis based on the assumption that neurodegenerative disorders, including Alzheimer’s disease, develop due to an increase in the concentration of harmful proteins. To prevent the development of diseases, it is only necessary to elaborate methods that reduce the concentration of amyloids and tau proteins. In this case, the main task was to develop a drug that would affect both categories of proteins.

The technique consists in using two already known vaccines AV-1959R and AV-1980R, on the basis of which Advax was generated by Nikolai Petrovsky. The newly created Advax substance allows to significantly reduce the amount of amyloid and tau-protein deposits in the brain tissues at any stage of the disease.

Testing Advax in mice has shown that the drug is highly effective for prevention purposes, reducing the risk of neurodegeneration. Even in the case when the experimental animals already had a high concentration of harmful proteins, the use of Advax could lead to body cleansing. According to scientists, the coming decade will be decisive in the elaboration of drugs that counteract the development of dementia and Alzheimer’s disease.

Previous articleHow to Maintain Good Memory & Mental Health?
Next articleThe 3 Main Strategies for EMF Protection